Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Podcasts|November 4, 2019
Atypical Antipsychotics in Bipolar Depression
Author(s)Chris Aiken, MD
We have nearly a dozen atypical antipsychotics to choose from, but do all of these work in bipolar disorder and which of them should we start with? Listen to the podcast.
Advertisement
We have nearly a dozen atypical antipsychotics to choose from, but do all of these work in bipolar disorder and which of them should we start with? Listen to the podcast.
Advertisement
Related to this article
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
5